Baxter Revenue 2010-2024 | BAX
Baxter annual/quarterly revenue history and growth rate from 2010 to 2024. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
- Baxter revenue for the quarter ending June 30, 2024 was $3.812B, a 2.83% increase year-over-year.
- Baxter revenue for the twelve months ending June 30, 2024 was $14.997B, a 3.97% increase year-over-year.
- Baxter annual revenue for 2023 was $14.813B, a 2.12% increase from 2022.
- Baxter annual revenue for 2022 was $14.506B, a 19.43% increase from 2021.
- Baxter annual revenue for 2021 was $12.146B, a 4.05% increase from 2020.
| Baxter Annual Revenue (Millions of US $) |
|
|---|---|
| 2023 | $14,813 |
| 2022 | $14,506 |
| 2021 | $12,146 |
| 2020 | $11,673 |
| 2019 | $11,362 |
| 2018 | $11,099 |
| 2017 | $10,584 |
| 2016 | $10,163 |
| 2015 | $9,968 |
| 2014 | $10,719 |
| 2013 | $9,413 |
| 2012 | $13,936 |
| 2011 | $13,893 |
| 2010 | $12,843 |
| 2009 | $12,562 |
| Baxter Quarterly Revenue (Millions of US $) |
|
|---|---|
| 2024-06-30 | $3,812 |
| 2024-03-31 | $3,592 |
| 2023-12-31 | $3,885 |
| 2023-09-30 | $3,708 |
| 2023-06-30 | $3,707 |
| 2023-03-31 | $3,513 |
| 2022-12-31 | $3,596 |
| 2022-09-30 | $3,609 |
| 2022-06-30 | $3,594 |
| 2022-03-31 | $3,707 |
| 2021-12-31 | $2,876 |
| 2021-09-30 | $3,226 |
| 2021-06-30 | $3,098 |
| 2021-03-31 | $2,946 |
| 2020-12-31 | $3,181 |
| 2020-09-30 | $2,972 |
| 2020-06-30 | $2,718 |
| 2020-03-31 | $2,802 |
| 2019-12-31 | $3,039 |
| 2019-09-30 | $2,851 |
| 2019-06-30 | $2,834 |
| 2019-03-31 | $2,638 |
| 2018-12-31 | $2,819 |
| 2018-09-30 | $2,761 |
| 2018-06-30 | $2,842 |
| 2018-03-31 | $2,677 |
| 2017-12-31 | $2,797 |
| 2017-09-30 | $2,707 |
| 2017-06-30 | $2,605 |
| 2017-03-31 | $2,475 |
| 2016-12-31 | $2,645 |
| 2016-09-30 | $2,558 |
| 2016-06-30 | $2,585 |
| 2016-03-31 | $2,375 |
| 2015-12-31 | $2,603 |
| 2015-09-30 | $2,487 |
| 2015-06-30 | $2,475 |
| 2015-03-31 | $2,403 |
| 2014-12-31 | $2,789 |
| 2014-09-30 | $2,709 |
| 2014-06-30 | $4,154 |
| 2014-03-31 | $3,848 |
| 2013-12-31 | $4,322 |
| 2013-09-30 | $3,710 |
| 2013-06-30 | $3,669 |
| 2013-03-31 | $3,448 |
| 2012-12-31 | $3,499 |
| 2012-09-30 | $3,477 |
| 2012-06-30 | $3,572 |
| 2012-03-31 | $3,388 |
| 2011-12-31 | $3,594 |
| 2011-09-30 | $3,479 |
| 2011-06-30 | $3,536 |
| 2011-03-31 | $3,284 |
| 2010-12-31 | $3,498 |
| 2010-09-30 | $3,224 |
| 2010-06-30 | $3,194 |
| 2010-03-31 | $2,927 |
| 2009-12-31 | $3,470 |
| 2009-09-30 | $3,145 |
| 2009-06-30 | $3,123 |
| 2009-03-31 | $2,824 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $19.749B | $14.813B |
| Baxter International Inc. is a global medical technology company. The company consists of renal and hospital products, providing items such as kidney-dialysis equipment, infusion pumps, and intravenous (IV) solutions. Baxter has been reporting through six revenue segments. Renal Care, Medication Delivery, Pharmaceuticals, Clinical Nutrition, Advanced Surgery, Acute Therapies and Other. Baxter's Renal segment primarily consists of Peritoneal Dialysis (PD) and Hemodialysis (HD) therapies. The portfolio addresses the needs of patients with kidney failure or kidney disease, and their healthcare providers, with a comprehensive range of therapeutic options across home, in-center, and hospital settings for better individualized care. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $196.139B | 25.33 |
| Stryker (SYK) | United States | $137.702B | 32.18 |
| Boston Scientific (BSX) | United States | $122.346B | 37.26 |
| Medtronic (MDT) | Ireland | $114.719B | 17.07 |
| EssilorLuxottica (ESLOY) | France | $106.985B | 0.00 |
| Haleon (HLN) | United Kingdom | $48.286B | 35.30 |
| Lonza Group Ag (LZAGY) | Switzerland | $46.218B | 0.00 |
| ResMed (RMD) | United States | $35.640B | 31.38 |
| Koninklijke Philips (PHG) | Netherlands | $29.674B | 22.55 |
| Terumo (TRUMY) | Japan | $28.204B | 39.83 |
| Zimmer Biomet Holdings (ZBH) | United States | $21.935B | 13.81 |
| Insulet (PODD) | United States | $16.507B | 69.45 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $13.465B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $9.256B | 30.67 |
| Demant (WILYY) | Denmark | $8.667B | 0.00 |
| BellRing Brands (BRBR) | United States | $7.864B | 33.25 |
| Lantheus Holdings (LNTH) | United States | $7.251B | 17.41 |
| ICU Medical (ICUI) | United States | $4.262B | 40.67 |
| Haemonetics (HAE) | United States | $3.918B | 19.38 |
| Neogen (NEOG) | United States | $3.612B | 37.89 |
| TG Therapeutics (TGTX) | United States | $3.612B | 38.25 |
| GN Store Nord (GNNDY) | Denmark | $3.576B | 21.54 |
| Prestige Consumer Healthcare (PBH) | United States | $3.536B | 17.62 |
| Perrigo (PRGO) | Ireland | $3.496B | 11.05 |
| Envista Holdings (NVST) | United States | $3.310B | 17.66 |
| QuidelOrtho (QDEL) | United States | $2.970B | 18.72 |
| Agios Pharmaceuticals (AGIO) | United States | $2.734B | 0.00 |
| Green Thumb Industries (GTBIF) | United States | $2.220B | 37.25 |
| Maravai LifeSciences Holdings (MRVI) | United States | $2.109B | 0.00 |
| LeMaitre Vascular (LMAT) | United States | $2.029B | 54.07 |
| Warby Parker (WRBY) | United States | $1.620B | 0.00 |
| InMode (INMD) | Israel | $1.444B | 9.19 |
| AdaptHealth (AHCO) | United States | $1.385B | 10.00 |
| AtriCure (ATRC) | United States | $1.384B | 0.00 |
| Owens & Minor (OMI) | United States | $1.213B | 9.36 |
| Verano Holdings (VRNOF) | United States | $1.199B | 0.00 |
| BioLife Solutions (BLFS) | United States | $1.115B | 0.00 |
| Evolus (EOLS) | United States | $1.032B | 0.00 |
| PetIQ (PETQ) | United States | $0.919B | 23.29 |
| Phibro Animal Health (PAHC) | United States | $0.895B | 18.57 |
| National Vision Holdings (EYE) | United States | $0.852B | 27.10 |
| Cresco Labs (CRLBF) | United States | $0.820B | 0.00 |
| Surmodics (SRDX) | United States | $0.549B | 116.58 |
| Quanterix (QTRX) | United States | $0.498B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.483B | 14.57 |
| ZimVie (ZIMV) | United States | $0.430B | 39.97 |
| Valneva SE (VALN) | France | $0.425B | 0.00 |
| Jin Medical (ZJYL) | China | $0.422B | 0.00 |
| Canopy Growth (CGC) | Canada | $0.397B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.386B | 0.00 |
| Cerus (CERS) | United States | $0.330B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.325B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.318B | 8.19 |
| Aurora Cannabis (ACB) | Canada | $0.314B | 0.00 |
| Biote (BTMD) | United States | $0.295B | 13.62 |
| Viemed Healthcare (VMD) | United States | $0.281B | 30.17 |
| Zynex (ZYXI) | United States | $0.262B | 45.89 |
| Sanara MedTech (SMTI) | United States | $0.254B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.233B | 15.45 |
| Omeros (OMER) | United States | $0.227B | 0.00 |
| Organigram Holdings (OGI) | Canada | $0.192B | 0.00 |
| MacroGenics (MGNX) | United States | $0.191B | 0.00 |
| Ayr Wellness (AYRWF) | United States | $0.191B | 0.00 |
| High Tide (HITI) | Canada | $0.157B | 65.00 |
| FitLife Brands (FTLF) | United States | $0.152B | 20.55 |
| Brainsway (BWAY) | Israel | $0.137B | 164.20 |
| TriSalus Life Sciences (TLSI) | United States | $0.122B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.122B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.117B | 0.00 |
| Veru (VERU) | United States | $0.114B | 0.00 |
| Fonar (FONR) | United States | $0.112B | 11.39 |
| Jushi Holdings (JUSHF) | United States | $0.105B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.098B | 24.00 |
| Zevia PBC (ZVIA) | United States | $0.085B | 0.00 |
| InterCure (INCR) | Israel | $0.083B | 14.08 |
| Cytosorbents (CTSO) | United States | $0.077B | 0.00 |
| Modular Medical (MODD) | United States | $0.077B | 0.00 |
| Safety Shot (SHOT) | United States | $0.072B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.068B | 0.00 |
| MariMed (MRMD) | United States | $0.065B | 0.00 |
| Exagen (XGN) | United States | $0.055B | 0.00 |
| Eagle Pharmaceuticals (EGRX) | United States | $0.053B | 3.44 |
| Allurion Technologies (ALUR) | United States | $0.041B | 0.00 |
| Apyx Medical (APYX) | United States | $0.041B | 0.00 |
| ImmuCell (ICCC) | United States | $0.028B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.026B | 0.00 |
| Nephros (NEPH) | United States | $0.019B | 0.00 |
| Flora Growth (FLGC) | United States | $0.017B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.014B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.013B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.009B | 0.00 |
| NeuroMetrix (NURO) | United States | $0.008B | 0.00 |
| GUARDION HEALTH (GHSI) | United States | $0.007B | 0.00 |
| Agape ATP (ATPC) | $0.007B | 0.00 | |
| Leafly Holdings (LFLY) | United States | $0.006B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.005B | 0.00 |
| Sharps Technology (STSS) | United States | $0.005B | 0.00 |
| Senestech (SNES) | United States | $0.001B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.001B | 0.00 |
| Akanda (AKAN) | United Kingdom | $0.000B | 0.00 |
| United-Guardian (UG) | United States | $0.000B | 21.89 |
| SNDL (SNDL) | Canada | $0.000B | 0.00 |